These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25950695)

  • 1. The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort.
    Shi YY; Li ZY; Zhao MH; Chen M
    Medicine (Baltimore); 2015 May; 94(18):e843. PubMed ID: 25950695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.
    Goupil R; Brachemi S; Nadeau-Fredette AC; Déziel C; Troyanov Y; Lavergne V; Troyanov S
    Clin J Am Soc Nephrol; 2013 Mar; 8(3):416-23. PubMed ID: 23220426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.
    Waki D; Nishimura K; Tokumasu H; Kadoba K; Mukoyama H; Saito R; Murabe H; Yokota T
    Medicine (Baltimore); 2020 Feb; 99(8):e19173. PubMed ID: 32080098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
    Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
    BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors correlated with immunosuppressant discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis patients.
    Murosaki T; Sato T; Nagatani K; Sato K; Minota S
    Int J Rheum Dis; 2020 Nov; 23(11):1587-1593. PubMed ID: 32996696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
    Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
    Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
    Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
    Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 33309337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Yamaguchi M; Katsuno T; Iwagaitsu S; Nobata H; Kinashi H; Banno S; Ito Y
    BMC Infect Dis; 2019 Jul; 19(1):664. PubMed ID: 31349802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center.
    Li ZY; Chang DY; Zhao MH; Chen M
    Arthritis Rheumatol; 2014 Jul; 66(7):1920-6. PubMed ID: 24623469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Predictors of Outcome in Patients with Anti-neutrophil Cytoplasmic Autoantibody-related Renal Vasculitis: Experiences from a Single-center.
    Pu L; Li GS; Zou YR; Zhang P; Wang L
    Chin Med J (Engl); 2017 Apr; 130(8):899-905. PubMed ID: 28397718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Morishita KA; Moorthy LN; Lubieniecka JM; Twilt M; Yeung RSM; Toth MB; Shenoi S; Ristic G; Nielsen SM; Luqmani RA; Li SC; Lee T; Lawson EF; Kostik MM; Klein-Gitelman M; Huber AM; Hersh AO; Foell D; Elder ME; Eberhard BA; Dancey P; Charuvanij S; Benseler SM; Cabral DA;
    Arthritis Rheumatol; 2017 Jul; 69(7):1470-1479. PubMed ID: 28371513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database.
    Sakai R; Tanaka E; Nishina H; Suzuki M; Yamanaka H; Harigai M
    Int J Rheum Dis; 2019 Nov; 22(11):1978-1984. PubMed ID: 31338986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
    Pagnoux C; Hogan SL; Chin H; Jennette JC; Falk RJ; Guillevin L; Nachman PH
    Arthritis Rheum; 2008 Sep; 58(9):2908-18. PubMed ID: 18759282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients.
    Lai QY; Ma TT; Li ZY; Chang DY; Zhao MH; Chen M
    J Rheumatol; 2014 Sep; 41(9):1849-55. PubMed ID: 25086076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.
    Rhee RL; Hogan SL; Poulton CJ; McGregor JA; Landis JR; Falk RJ; Merkel PA
    Arthritis Rheumatol; 2016 Jul; 68(7):1711-20. PubMed ID: 26814428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings.
    Mahajan AP; Hogan JW; Snyder B; Kumarasamy N; Mehta K; Solomon S; Carpenter CC; Mayer KH; Flanigan TP
    J Acquir Immune Defic Syndr; 2004 May; 36(1):567-75. PubMed ID: 15097299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients.
    Matsumoto Y; Sada KE; Otsuka F; Takano M; Toyota N; Sugiyama K; Wakabayashi H; Kawabata T; Makino H
    Rheumatol Int; 2012 Oct; 32(10):2999-3005. PubMed ID: 21898055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.